newsfilter
← Latest News
PR Newswire·

BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development

VANCOUVER, British Columbia, June 14, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its Pre-IND request for a